https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-302016-04-27 00:00:002019-02-15 09:13:31Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-21 / Radiat Oncol 2016 Apr;11:60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-21 / Radiat Oncol 2016 Apr;11:602016-04-21 00:00:002019-02-15 08:45:46Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-20 / Oncolytic Virother 2016;5:27-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-20 / Oncolytic Virother 2016;5:27-342016-04-20 00:00:002019-02-15 09:23:14Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-18 / Int J Hyperthermia 2016 06;32(4):446-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-18 / Int J Hyperthermia 2016 06;32(4):446-542016-04-18 00:00:002019-02-15 09:18:10Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-906
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-9062016-04-15 00:00:002019-02-15 08:45:11Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-15 / Hepatology 2016 08;64(2):456-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-15 / Hepatology 2016 08;64(2):456-722016-04-15 00:00:002016-04-15 00:00:00Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-04-11 / Cancer Res. 2016 06;76(12):3496-506
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-04-11 / Cancer Res. 2016 06;76(12):3496-5062016-04-11 00:00:002019-02-15 08:49:43T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-30 / Radiat Oncol J 2016 Mar;34(1):34-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-30 / Radiat Oncol J 2016 Mar;34(1):34-442016-03-30 00:00:002019-02-15 08:39:27Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-26 / Semin. Cancer Biol. 2016 06;37-38:96-105
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-26 / Semin. Cancer Biol. 2016 06;37-38:96-1052016-03-26 00:00:002019-02-15 09:18:09Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-24 / Thorac Cancer 2016 Jul;7(4):422-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-24 / Thorac Cancer 2016 Jul;7(4):422-72016-03-24 00:00:002019-02-15 09:18:22Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLC
